| Active substance |
Dabigatran |
| Also known as |
Dabigatran |
| Blood pressure |
Typically does not affect blood pressure |
| Chemical name |
N-{2-[4-(N'-{[(Hexyloxy)carbonyl]carbamimidoyl}carbamimidoyl)phenylaminomethyl]-1-methyl-1H-benzimidazol-5-ylcarbonyl}-N-pyridin-2-yl-beta-alanine ethyl ester |
| Dosage (medical) |
150 mg or 110 mg twice daily depending on renal function |
| Dosage (sports) |
Not applicable as it is not used for sports enhancement |
| Effects |
Reduces the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation |
| FORM |
60 caps x 75 mg |
| Formula |
C34H41N7O5 |
| Half-life |
12 to 17 hours |
| Hepatotoxicity |
No significant hepatotoxicity |
| Lab Test |
Monitoring of renal function and possibly coagulation parameters |
| Main action |
Anticoagulant |
| Side effects |
Bleeding, gastrointestinal upset, heartburn, nausea |
| Storage conditions |
Store at room temperature away from moisture and heat |
| Substance class |
Direct thrombin inhibitor |
| Trade name |
Pradaxa |
| Use in sports |
None, as it does not enhance athletic performance |
| Water Retention |
No significant water retention |
| Manufacturer |
Boehringer |
